---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-22-000036"
form_type: "8-K/A"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2022-08-17T23:59:59+00:00"
generated_at: "2026-06-23T23:05:51.142731+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Travere Therapeutics appoints Christopher Cline as CFO with $430k salary, equity grants

## Summary
- Christopher Cline named CFO effective September 1, 2022, replacing retiring Laura Clague.
- Annual base salary of $430,000; target annual bonus of 50% of base salary.
- Equity grants: stock option for 48,000 shares, Time-Based RSU for 5,000 shares, PSUs for 9,840 shares.
- Laura Clague steps down as CFO on August 31, 2022, remains through Q1 2023 for transition.
- Severance provisions include 12-month cash continuation and accelerated vesting under certain conditions.

## SEC filing metadata
- accession: 0001438533-22-000036
- form_type: 8-K/A
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2022-08-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/0001438533-22-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/tvtx-20220419.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-22-000036
- JSON: https://secwatch.observer/filing/0001438533-22-000036.json
- Plain text: https://secwatch.observer/filing/0001438533-22-000036.txt

## Key facts
- Executive change
  Laura Clague departed as Chief Financial Officer at Travere Therapeutics, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/0001438533-22-000036-index.htm
- Executive change
  Christopher Cline was appointed as Chief Financial Officer at Travere Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of September 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/0001438533-22-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.